التفاصيل البيبلوغرافية
العنوان: |
Clinical efficacy and safety of chimeric antigen receptor T‐cell therapy for mantle cell lymphoma with secondary central nervous system involvement. |
المؤلفون: |
Ryan, Christine E., Zon, Rebecca L., Redd, Robert, Fisher, David C., Shouval, Roni, Kumar, Anita, Crombie, Jennifer L., Sadrzadeh, Hossein, Kim, Austin I., Nayak, Lakshmi, Chukwueke, Ugonma N., Jacobson, Caron A., Frigault, Matthew J., Palomba, M. Lia, Armand, Philippe, Epstein‐Peterson, Zachary, Merryman, Reid W. |
المصدر: |
British Journal of Haematology; Dec2023, Vol. 203 Issue 5, p774-780, 7p |
مصطلحات موضوعية: |
MANTLE cell lymphoma, CHIMERIC antigen receptors, CENTRAL nervous system, T cells, CELLULAR therapy |
مستخلص: |
Summary: Data describing outcomes of chimeric antigen receptor (CAR) T‐cell therapy in patients with secondary central nervous system (SCNS) involvement of mantle cell lymphoma (MCL) are limited. We identified 10 patients with MCL and SCNS involvement treated with anti‐CD19 CAR T‐cell therapy at three US academic centres. Frequent objective responses were observed in the CNS (86%) and systemically (90%), and the 1‐year progression‐free survival was 47%. Seven patients developed immune‐effector‐cell‐associated‐neurotoxicity‐syndrome (n = 2 Grade 1, n = 5 Grade 3). Our results suggest that anti‐CD19 CAR T‐cell therapy in this setting is feasible and additional data regarding neurotoxicity in this population may be warranted. [ABSTRACT FROM AUTHOR] |
|
Copyright of British Journal of Haematology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
قاعدة البيانات: |
Complementary Index |